Create account

Coverage dated October 27, 2026

Novartis raised its profit outlook even as a drug trial failure led to a $1.9 billion charge

Headline from Quartz

Core operating income guidance moved from a low-single-digit decline to flat or low-single-digit growth; net income fell 70%

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    Novartis Raises Profit Outlook on Growth of New Medicines (opens Bloomberg)

    Published

    Bloomberg's feed description

    Novartis AG raised its profit outlook for the year as growth from newer medicines increasingly offset the hit from generic competition to former blockbuster Entresto.

  2. Independent Journal Review

    Novartis Raises Outlook Despite 70% Q3 Profit Drop (opens Independent Journal Review)

    Published

    Independent Journal Review's feed description

    Novartis raised 2026 core operating income guidance to flat or low-single-digit growth while Q3 net income fell 70% to $1.196 billion on a $1.9 billion del-desiran charge.

  3. Quartz

    Novartis raised its profit outlook even as a drug trial failure led to a $1.9 billion charge (opens Quartz)

    Published

    Quartz's feed description

    Core operating income guidance moved from a low-single-digit decline to flat or low-single-digit growth; net income fell 70%